<p>Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Published:2019-05 Issue: Volume:Volume 11 Page:4449-4459
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Hu Xing-sheng,Han Xiao-hong,Yang Sheng,Li Ning,Wang Lin,Song Yuan-yuan,Mu Hua,Shi Yuan-kai

Publisher

Informa UK Limited

Subject

Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06

2. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11

3. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States;Pharmacological Research;2023-08

4. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review;Journal of Oncology Pharmacy Practice;2023-05-12

5. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism;Molecules;2021-11-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP